Successful autologous bone marrow transplantation in second remission of malignant histiocytosis.
This report describes an 18-year-old man with disseminated malignant histiocytosis (MH). The patient initially attained complete remission (CR1) with conventional chemotherapy and then relapsed 14 months later. In second complete remission (CR2) 2 years and 8 months after initial diagnosis, an autologous bone marrow transplantation (ABMT) was undertaken following conditioning with the BEAM regimen. Bone marrow collected in CR2 was incubated with mafosfamide at a dose adjusted to the individual sensitivity of normal CFU-GM according to our current protocol. At the time of writing, 4 years post-transplant, this patient remains disease free. This is the first report of ABMT with marrow treated in vitro by mafosfamide in MH.
Cazin
B
B
Unité de greffe de moelle osseuse, Hôpital St Antoine, Paris, France.
Gorin
N C
NC
Jouet
J P
JP
Laporte
J P
JP
Fenaux
P
P
Walter
M P
MP
Najman
A
A
Gosselin
B
B
Bauters
F
F
D000293:Adolescent; D001761:Bleomycin / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D054747:Histiocytic Sarcoma / Q000188:drug therapy / Q000601:surgery*; D006801:Humans; D008297:Male; D011241:Prednisone / Q000627:therapeutic use; D012074:Remission Induction; D014182:Transplantation, Autologous; D014750:Vincristine / Q000627:therapeutic use
D001761:Bleomycin; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone